BENRALIZUMAB FOR USE IN THE TREATMENT OF ASTHMA BY INCREASING FORCED EXPIRATORY VOLUME

MX435174BActive Publication Date: 2026-06-12ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
ASTRAZENECA AB
Filing Date
2016-01-29
Publication Date
2026-06-12

AI Technical Summary

Technical Problem

Asthma remains a major source of morbidity despite the use of long-acting bronchodilators and inhaled corticosteroids, with patients experiencing relapses and reduced lung function due to eosinophilic inflammation, and existing treatments face challenges with compliance and efficacy.

Method used

Administering benralizumab, a humanized monoclonal antibody that targets the interleukin-5 receptor alpha, to induce apoptosis of eosinophils and basophils, thereby increasing forced expiratory volume in one second (FEVi) in asthmatic patients, particularly those with high eosinophil counts.

Benefits of technology

Benralizumab significantly increases FEVi by at least 0.1 L within 4 weeks, with greater improvements observed in patients receiving higher doses, improving lung function and reducing asthma exacerbations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Methods for increasing forced expiratory volume in one second (FEV1) in a patient with asthma are presented, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art